Characteristics of patient by donor type
| . | All . | MSD . | MUD . | UCB . | dUCB . | P* . |
|---|---|---|---|---|---|---|
| Patients by stem cell source | ||||||
| N (% of total) | 317 (100) | 61 (19) | 73 (23) | 122 (38) | 61 (19) | |
| Median follow-up | 1730 | 1969 | 1468 | 1631 | 1877 | |
| Median age at HSCT (range) | 10 (0.42-21) | 8.7 (0.63-21) | 11 (1-20) | 7.9 (0.42-20) | 13 (1.1-20) | <.001† |
| Remission status at HSCT, n (%) | .0063‡ | |||||
| CR1 | 155 (49) | 42 (69) | 33 (45) | 55 (45) | 25 (41) | |
| CR2 | 162 (51) | 19 (31) | 40 (55) | 67 (55) | 36 (59) | |
| Baseline risk stratification, n (%) | <.001† | |||||
| High | 237 (75) | 31 (51) | 55 (75) | 102 (84) | 49 (80) | |
| CNS status at HSCT, n (%) | .6 | |||||
| CNS-disease | 86 (27) | 20 (33) | 16 (22) | 33 (27) | 17 (28) | |
| Center of HSCT, n (%) | <.001† | |||||
| Australia | 24 (7.6) | 8 (13) | 1 (1.4) | 11 (9) | 4 (6.6) | |
| Denver | 48 (15) | 14 (23) | 11 (15) | 18 (15) | 5 (8.2) | |
| Duke | 58 (18) | 16 (26) | 3 (4.1) | 30 (25) | 9 (15) | |
| Gosh | 16 (5) | 4 (6.6) | 6 (8.2) | 6 (4.9) | 0 (0) | |
| Manchester | 39 (12) | 6 (9.8) | 23 (32) | 7 (5.7) | 3 (4.9) | |
| Minneapolis | 52 (16) | 0 (0) | 10 (14) | 13 (11) | 29 (48) | |
| Seattle | 37 (12) | 6 (9.8) | 14 (19) | 8 (6.6) | 9 (15) | |
| Utrecht | 43 (14) | 7 (11) | 5 (6.8) | 29 (24) | 2 (3.3) | |
| Primary cause of death, n (%) | .14 | |||||
| GVHD | 14 (13) | 1 (6.2) | 1 (4.2) | 7 (17) | 5 (18) | |
| Infection | 12 (11) | 2 (12) | 0 (0) | 5 (12) | 5 (18) | |
| MOF | 4 (3.6) | 1 (6.2) | 2 (8.3) | 1 (2.4) | 0 (0) | |
| Pulmonary disease (NOS) | 9 (8.2) | 1 (6.2) | 2 (8.3) | 3 (7.1) | 3 (11) | |
| Other | 8 (7.3) | 2 (12) | 2 (8.3) | 3 (7.1) | 1 (3.6) | |
| Relapse | 63 (57) | 9 (56) | 17 (71) | 23 (55) | 14 (50) |
| . | All . | MSD . | MUD . | UCB . | dUCB . | P* . |
|---|---|---|---|---|---|---|
| Patients by stem cell source | ||||||
| N (% of total) | 317 (100) | 61 (19) | 73 (23) | 122 (38) | 61 (19) | |
| Median follow-up | 1730 | 1969 | 1468 | 1631 | 1877 | |
| Median age at HSCT (range) | 10 (0.42-21) | 8.7 (0.63-21) | 11 (1-20) | 7.9 (0.42-20) | 13 (1.1-20) | <.001† |
| Remission status at HSCT, n (%) | .0063‡ | |||||
| CR1 | 155 (49) | 42 (69) | 33 (45) | 55 (45) | 25 (41) | |
| CR2 | 162 (51) | 19 (31) | 40 (55) | 67 (55) | 36 (59) | |
| Baseline risk stratification, n (%) | <.001† | |||||
| High | 237 (75) | 31 (51) | 55 (75) | 102 (84) | 49 (80) | |
| CNS status at HSCT, n (%) | .6 | |||||
| CNS-disease | 86 (27) | 20 (33) | 16 (22) | 33 (27) | 17 (28) | |
| Center of HSCT, n (%) | <.001† | |||||
| Australia | 24 (7.6) | 8 (13) | 1 (1.4) | 11 (9) | 4 (6.6) | |
| Denver | 48 (15) | 14 (23) | 11 (15) | 18 (15) | 5 (8.2) | |
| Duke | 58 (18) | 16 (26) | 3 (4.1) | 30 (25) | 9 (15) | |
| Gosh | 16 (5) | 4 (6.6) | 6 (8.2) | 6 (4.9) | 0 (0) | |
| Manchester | 39 (12) | 6 (9.8) | 23 (32) | 7 (5.7) | 3 (4.9) | |
| Minneapolis | 52 (16) | 0 (0) | 10 (14) | 13 (11) | 29 (48) | |
| Seattle | 37 (12) | 6 (9.8) | 14 (19) | 8 (6.6) | 9 (15) | |
| Utrecht | 43 (14) | 7 (11) | 5 (6.8) | 29 (24) | 2 (3.3) | |
| Primary cause of death, n (%) | .14 | |||||
| GVHD | 14 (13) | 1 (6.2) | 1 (4.2) | 7 (17) | 5 (18) | |
| Infection | 12 (11) | 2 (12) | 0 (0) | 5 (12) | 5 (18) | |
| MOF | 4 (3.6) | 1 (6.2) | 2 (8.3) | 1 (2.4) | 0 (0) | |
| Pulmonary disease (NOS) | 9 (8.2) | 1 (6.2) | 2 (8.3) | 3 (7.1) | 3 (11) | |
| Other | 8 (7.3) | 2 (12) | 2 (8.3) | 3 (7.1) | 1 (3.6) | |
| Relapse | 63 (57) | 9 (56) | 17 (71) | 23 (55) | 14 (50) |